Erythropoiesis stimulating agent (ESA) treatment decisions and guidelines based on the questionable assumption that Hb should be normalized or nearly normalized in the majority of CKD patients need to be reconsidered [5]. The gene discussed is GSTM1; the disease is chronic kidney disease.